Results 141 to 150 of about 436,731 (247)

Dietary melatonin and its benefits on cardiovascular disease

open access: yesBritish Journal of Pharmacology, EarlyView.
Cardiovascular disease remains the leading cause of mortality globally, with a disproportionate burden in low‐ and middle‐income countries. Melatonin, a hormone primarily produced by the pineal gland, exhibits notable antioxidant, anti‐inflammatory and immunomodulatory properties that may confer cardiovascular benefits.
Karabo Tisane   +2 more
wiley   +1 more source

Positive modulation of glucagon‐like peptide 1 (GLP‐1) receptor by endogenous haemorphins with implications in glucose metabolism and diabetes

open access: yesBritish Journal of Pharmacology, EarlyView.
Haemorphins act on GLP‐1 receptor (GLP‐1R) activity and signalling in a positive allosteric manner. This leads to potentiated GLP‐1‐mediated activity and signalling, as well as insulin synthesis, which may have implications for glucose metabolism and, thereby, diabetes and obesity. (The graph was created in BioRender.com).
Farheen Badrealam Khan   +13 more
wiley   +1 more source

Cardiomyopathies of endocrine origin: A state-of-the-art review. [PDF]

open access: yesWorld J Cardiol
Fuentes-Mendoza JM   +9 more
europepmc   +1 more source

Emerging insights into amino acid metabolism in the heart: implications for cardiovascular diseases and therapeutic targeting

open access: yesBritish Journal of Pharmacology, EarlyView.
As a metabolically versatile organ, the heart is capable of generating energy from a wide range of substrates. Although fatty acid and glucose metabolism in the heart have been extensively studied, the contribution of amino acid metabolism to cardiac physiology and disease is gaining increasing attention.
Tayyiba Azam   +6 more
wiley   +1 more source

GSDME in cardiovascular diseases: research system and contemporary progress. [PDF]

open access: yesFront Immunol
Yang Z   +8 more
europepmc   +1 more source

Inborn errors of immunity in children with neuroinflammation

open access: yesDevelopmental Medicine &Child Neurology, EarlyView.
Abstract Inborn errors of immunity (IEIs), an expanding group of monogenic disorders with diverse clinical manifestations, are increasingly recognized to include neuroinflammatory disease. Examples of diseases included under this umbrella are Aicardi–Goutières syndrome, deficiency of adenosine deaminase 2, familial haemophagocytic lymphohistiocytosis ...
Eppie M Yiu   +5 more
wiley   +1 more source

Cardiovascular Outcomes in Semaglutide Versus Tirzepatide Users With Obesity and Atherosclerotic Disease: A Target Trial Emulation

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Semaglutide, a glucagon‐like peptide‐1 (GLP‐1) receptor agonist, is approved for cardiovascular risk reduction in individuals with overweight or obesity and cardiovascular disease. Whether tirzepatide, a dual GLP‐1 and glucose‐dependent insulinotropic polypeptide receptor agonist, has similar cardiovascular benefits remains unknown.
Gwen Aubrac   +5 more
wiley   +1 more source

The sorting nexin Snx21 promotes flotillin‐mediated endocytosis

open access: yesThe FEBS Journal, EarlyView.
In this study, we describe a novel function of the previously uncharacterized Snx21 protein as a specific positive regulator of flotillin‐mediated endocytic trafficking. Snx21 is recruited to endosomal membranes via binding to PI(3)P, and it colocalizes with flotillins on the surface of late endosomes.
Tamás Maruzs   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy